AbbVie stock: acquired R&D costs trim its 2026 EPS range

The central disclosed change is a $0.11-per-share reduction to AbbVie’s 2026 adjusted diluted EPS guidance for $216 million of Q3 acquired IPR&D and milestone expense. The company’s release lists the full-year adjusted diluted EPS range, including that expense, at $13.76 to $13.96. AbbVie Q3 FY2026 earnings release

The release also shows the before-and-after arithmetic: previously announced guidance excluding the Q3 item was $13.87 to $14.07; subtracting $0.11 from each endpoint produces the newly stated $13.76 to $13.96 range. That calculation is consistent with the release’s table. It is a guidance adjustment, not a report of Q3 adjusted EPS actually earned.

There is an important limit to what this print can establish. The attached release text contains no Q3 revenue, reported EPS, free cash flow or margin results. The quarterly table supplied for comparison ends at Q2 FY2026, so it cannot support an actual-versus-year-ago scorecard for Q3.

The expense reduces the company’s stated adjusted earnings outlook, but the disclosed item is specific: acquired IPR&D and milestones. The release does not identify the assets, explain the scientific or commercial rationale, or state whether further such costs will occur. That makes the EPS reduction real as guidance, while leaving its investment return and strategic value unassessed here.

AbbVie explicitly says its 2026 adjusted diluted EPS guidance excludes any acquired IPR&D and milestone expense that may be incurred beyond Q3 because those costs cannot be reliably forecast. The published range therefore carries a defined exclusion: investors should not read $13.76 to $13.96 as a ceiling on this category of expense. AbbVie Q3 FY2026 earnings release

For this earnings update, the lack of operating results matters as much as the guidance adjustment. The evidence does not show whether revenue growth, operating margins or cash conversion continued the pattern in the prior quarter. It therefore does not justify changing the underlying business assumptions from the previous coverage.

We carry forward the prior base fair value of $246.70 per share, unchanged. That is below the current share price of $265.78, but the gap is not a new conclusion from this Q3 release. At that price, the shares are fairly valued relative to the estimate; the release alone does not contain enough operating information to recalculate it.

The prior scenario framework is retained: Bear at $190 per share, Base at $246.70 and Bull at $300, with respective probabilities of 25%, 50% and 25%. These are carried-forward analyst assumptions, not figures disclosed by AbbVie. The base value is a direct equity valuation: $436.91 billion of assumed equity value divided by 1.771 billion shares equals approximately $246.70 per share. That share count is the latest XBRL point value; no new diluted-share figure appears in the release. At $265.78, the share price is about 7.7% above the carried-forward base estimate.

The report’s P/E and free-cash-flow yield are supplied trailing measures, not Q3 results. The attached release does not change those reported-period inputs. An intrinsic-value estimate would require a refreshed view of future earnings and cash flows; this release adds an expense adjustment but no new operating data with which to make that revision.

The carried-forward valuation would need reconsideration if subsequent reporting showed that acquired IPR&D and milestone costs recur at a level that materially reduces earnings or cash available to shareholders. The present release flags the forecasting uncertainty but does not quantify any costs beyond Q3.

The other unresolved test is operating performance: Q3 revenue, margins and cash flow could confirm or contradict the prior thesis, but they are not present in the attached Q3 release text. Until those results are available in a source document, calling the quarter a beat or miss would be pretending that guidance is a result.